A Single-Center, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of a Single Dose of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults
Latest Information Update: 21 Apr 2022
At a glance
- Drugs Crisantaspase (Primary) ; Crisantaspase (Primary)
- Indications Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 01 Dec 2019 New trial record
- 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.